ResearcherHeidelberg UniversityActive in the last 2 years
Mohammed Al‐Saeedi
Matched on ORCID iD 0000-0002-0583-4472; OpenAlex author ID A5103083621. Sources: OpenAlex.
Their work
- Papers
- 10 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 26
2022: 1 paper · 2023: 2 papers · 2024: none · 2025: 2 papers · 2026: 5 papers
Papers 10
- Impact of sarcopenia and myosteatosis on early and long-term survival after surgical resection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2026.04.007↗
- Preoperative Surgical or Endoscopic Bile Duct Drainage in Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006407↗
- Neoadjuvant Treatment is a Risk Factor for Clinically Relevant Chyle Leak (ISGPS Grade B/C) After Pancreatic Cancer Resection: A Retrospective Cohort Study. Last author DOI 10.1245/s10434-025-18698-4↗
- ASO Visual Abstract: Neoadjuvant Treatment is a Risk Factor for Clinically Relevant Chyle Leak (ISGPS Grade B/C) after Pancreatic Cancer Resection: A Retrospec… Last author DOI 10.1245/s10434-025-18864-8↗
- Optimal Time Between Completion of Preoperative Chemotherapy and Surgery for Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-026-19264-2↗
- Radical antegrade modular pancreatosplenectomy versus conventional left pancreatectomy for pancreatic cancer: study protocol for the multicentre randomized cli… Co-author DOI 10.1093/bjsopen/zraf169↗
- Challenges and adaptations in pancreatic cancer surgery during the COVID-19 pandemic in a high-volume center. Co-author DOI 10.1186/s12885-025-13512-6↗
- A scan of all coding region variants of the human genome, identifies 13q12.2-rs9579139 and 15q24.1-rs2277598 as novel risk loci for pancreatic ductal adenocarc… Co-author DOI 10.1093/carcin/bgad056↗
- Distal Pancreatectomy With En Bloc Celiac Axis Resection (DP-CAR) for Locally Advanced Pancreatic Cancer: A Safe and Effective Procedure. Co-author DOI 10.1097/sla.0000000000005866↗
- Actual Five-year Survival After Upfront Resection for Pancreatic Ductal Adenocarcinoma: Who Beats the Odds? Co-author DOI 10.1097/sla.0000000000004147↗
Closest collaborators
The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Martin Loos · 8 shared papers, 2023–2026 · strength 1.99
- Paper Optimal Time Between Completion of Preoperative Chemotherapy and Surgery for Locally Advanced Pancreatic Cancer. DOI 10.1245/s10434-026-19264-2↗
- Paper Impact of sarcopenia and myosteatosis on early and long-term survival after surgical resection of pancreatic ductal ade… DOI 10.1016/j.pan.2026.04.007↗
- Paper Neoadjuvant Treatment is a Risk Factor for Clinically Relevant Chyle Leak (ISGPS Grade B/C) After Pancreatic Cancer Res… DOI 10.1245/s10434-025-18698-4↗
- Thilo Hackert · 7 shared papers, 2022–2026 · strength 1.56
- Paper Optimal Time Between Completion of Preoperative Chemotherapy and Surgery for Locally Advanced Pancreatic Cancer. DOI 10.1245/s10434-026-19264-2↗
- Paper Neoadjuvant Treatment is a Risk Factor for Clinically Relevant Chyle Leak (ISGPS Grade B/C) After Pancreatic Cancer Res… DOI 10.1245/s10434-025-18698-4↗
- Paper ASO Visual Abstract: Neoadjuvant Treatment is a Risk Factor for Clinically Relevant Chyle Leak (ISGPS Grade B/C) after … DOI 10.1245/s10434-025-18864-8↗
- Thomas P. Hank · 6 shared papers, 2022–2026 · strength 1.47
- Paper Optimal Time Between Completion of Preoperative Chemotherapy and Surgery for Locally Advanced Pancreatic Cancer. DOI 10.1245/s10434-026-19264-2↗
- Paper Impact of sarcopenia and myosteatosis on early and long-term survival after surgical resection of pancreatic ductal ade… DOI 10.1016/j.pan.2026.04.007↗
- Paper Neoadjuvant Treatment is a Risk Factor for Clinically Relevant Chyle Leak (ISGPS Grade B/C) After Pancreatic Cancer Res… DOI 10.1245/s10434-025-18698-4↗
- Markus Wolfgang Büchler · 6 shared papers, 2022–2026 · strength 1.30
- Paper Optimal Time Between Completion of Preoperative Chemotherapy and Surgery for Locally Advanced Pancreatic Cancer. DOI 10.1245/s10434-026-19264-2↗
- Paper Impact of sarcopenia and myosteatosis on early and long-term survival after surgical resection of pancreatic ductal ade… DOI 10.1016/j.pan.2026.04.007↗
- Paper Preoperative Surgical or Endoscopic Bile Duct Drainage in Pancreatic Cancer. DOI 10.1097/sla.0000000000006407↗
- Oliver Strobel · 4 shared papers, 2022–2026 · strength 0.91
- Paper Neoadjuvant Treatment is a Risk Factor for Clinically Relevant Chyle Leak (ISGPS Grade B/C) After Pancreatic Cancer Res… DOI 10.1245/s10434-025-18698-4↗
- Paper ASO Visual Abstract: Neoadjuvant Treatment is a Risk Factor for Clinically Relevant Chyle Leak (ISGPS Grade B/C) after … DOI 10.1245/s10434-025-18864-8↗
- Paper Preoperative Surgical or Endoscopic Bile Duct Drainage in Pancreatic Cancer. DOI 10.1097/sla.0000000000006407↗
- Ingmar Florin Rompen · 2 shared papers, 2026 · strength 0.57
- Paper Optimal Time Between Completion of Preoperative Chemotherapy and Surgery for Locally Advanced Pancreatic Cancer. DOI 10.1245/s10434-026-19264-2↗
- Paper Impact of sarcopenia and myosteatosis on early and long-term survival after surgical resection of pancreatic ductal ade… DOI 10.1016/j.pan.2026.04.007↗
- Carl-Stephan Leonhardt · 2 shared papers, 2026 · strength 0.54
- Paper Neoadjuvant Treatment is a Risk Factor for Clinically Relevant Chyle Leak (ISGPS Grade B/C) After Pancreatic Cancer Res… DOI 10.1245/s10434-025-18698-4↗
- Paper ASO Visual Abstract: Neoadjuvant Treatment is a Risk Factor for Clinically Relevant Chyle Leak (ISGPS Grade B/C) after … DOI 10.1245/s10434-025-18864-8↗
- Frank Pianka · 2 shared papers, 2025–2026 · strength 0.45
- Rosa Klotz · 2 shared papers, 2025–2026 · strength 0.45
- Benedict Kinny‐Köster · 2 shared papers, 2023–2026 · strength 0.41
- Anna‐Katharina König · 2 shared papers, 2022–2026 · strength 0.40
- Paper Impact of sarcopenia and myosteatosis on early and long-term survival after surgical resection of pancreatic ductal ade… DOI 10.1016/j.pan.2026.04.007↗
- Paper Actual Five-year Survival After Upfront Resection for Pancreatic Ductal Adenocarcinoma: Who Beats the Odds? DOI 10.1097/sla.0000000000004147↗
- Martin A. Schneider · 2 shared papers, 2022–2026 · strength 0.37
- Markus K. Diener · 2 shared papers, 2022–2025 · strength 0.32
- Paper Radical antegrade modular pancreatosplenectomy versus conventional left pancreatectomy for pancreatic cancer: study pro… DOI 10.1093/bjsopen/zraf169↗
- Paper Actual Five-year Survival After Upfront Resection for Pancreatic Ductal Adenocarcinoma: Who Beats the Odds? DOI 10.1097/sla.0000000000004147↗
- Marionna Cathomas · 1 shared paper, 2026 · strength 0.29
- Christoph Kahlert · 1 shared paper, 2026 · strength 0.29
- Miriam Klauß · 1 shared paper, 2026 · strength 0.28
- Philipp Mayer · 1 shared paper, 2026 · strength 0.28
- Niels Siegel · 1 shared paper, 2026 · strength 0.28
- Felix Jakob Hüttner · 1 shared paper, 2025 · strength 0.20
- Magdalena Holze · 1 shared paper, 2025 · strength 0.20
- Christoph W. Michalski · 1 shared paper, 2025 · strength 0.20
- Dirk Jäger · 1 shared paper, 2022 · strength 0.12
- Willem Niesen · 1 shared paper, 2022 · strength 0.12
- Matthias M. Gaida · 1 shared paper, 2022 · strength 0.12
- Christoph Springfeld · 1 shared paper, 2022 · strength 0.12
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.